American Diabetes Association (ADA) 2020

Approaches to and inertia in cardiovascular and renal risk management of Type 2 diabetes patients in primary care: Results from a global quantitative survey

A Direct AMPK Activator Reduces Liver Steatosis in a Mouse Model of NASH

Quantification of GLP-1R trafficking in primary β-cells in response to different ligands

Discrepancy between single-cell RNA sequencing and protein expression assessments of GLP-1R heterogeneity in β-cells

Cotadutide (MEDI0382), a Dual Receptor Agonist With Glucagon like Peptide 1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Stores

Cotadutide (MEDI0382), A Dual Receptor Agonist With Glucagon-like Peptide-1 and Glucagon Activity, Is Well-tolerated (≤ 600 µg) With Robust Effects On Blood Glucose In Patients With T2DM

Cotadutide, a GLP-1/GCG receptor dual-agonist  improves insulin sensitivity and restores normal insulin secretory capacity in DIO mice

Once-weekly Exenatide Effects on eGFR Slope and UACR as a Function of Baseline UACR: an EXSCEL Trial Post-Hoc Analysis

Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analyses from the DECLARE-TIMI 58 Trial

Effect of dapagliflozin on the incidence of diabetes: A prespecified exploratory analysis from DAPA-HF

Effects of Long-term Dapagliflozin Treatment on Hemorheology, Leukocyte Activation, and Oxidative Stress (D-PATH Study)

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients with Type 2 Diabetes (DAPA-CAN)

Effects of dapagliflozin in DAPA HF according to background glucose lowering therapy (GLT)

Cardiorenal Outcomes with Dapagliflozin vs. Placebo by Baseline Glucose Lowering Agents Analyses from DECLARE-TIMI 58

Dapagliflozin Suppresses Adipose Fatty Acid Accumulation in Rats Fed on High-Fat Diet but not on Normal Chow

Changes in plasma levels of liver enzymes in response to dapagliflozin, metformin or exercise in people with prediabetes: The PRE-D Trial

Effects of Dapagliflozin, Metformin, or Exercise on Plasma Glucagon Concentrations in Individuals with Prediabetes: The PRE-D Trial

Dapagliflozin promotes adipose beiging and lipolysis and reduces adipocyte size in the obese prediabetic dog

HbA1c < 7.0% 6 months after initiation of second-line therapy in patients with uncontrolled type 2 diabetes is associated with good glycemic control at 3 years: the DISCOVER study

Effects of second-line metformin combination therapies on weight, HbA1c and risk of hypoglycemia over 3 years: the DISCOVER study

Quality of Life in People with Type 2 Diabetes Following Initiation of Second-Line Therapy: DISCOVER

Impact Of Diabetes-related Factors and Background Antihyperglycemic Therapy on the Efficacy And Safety of Ticagrelor added to Aspirin: Insights from the THEMIS Trial